ITHS Tools
Login
Need Help? Have a Question?
Connect with Us

Computational Pipeline for Spatial Transcriptomics Analysis of Glioblastoma

Computational Pipeline for Spatial Transcriptomics Analysis of Glioblastoma

TRANSLATIONAL SCIENCE BENEFITS MODEL PROFILE

Summary

During this project, the team built a computational pipeline with five modules, each with its own algorithm to analyze input data. We used coding techniques within the pipeline to identify aggressive cell populations within glioblastoma tumors. We use this technique to understand differences within tumors. We looked at over 2.7 million cells from 12 patients. For each part of the tumor, it shows what types of cells are there, which genes are active, and how the cells behave. This technique help us identify biomarkers linked to the most aggressive tumor cells, which are then targets for new drugs or therapies that block or slow down the growth of these aggressive cells. Ultimately, we believe this will lead to more targeted, effective treatments for patients suffering from aggressive glioblastomas.

Significance

Glioblastoma is one of the most aggressive and deadly brain cancers, with a median survival of only 15 months, affecting 3 people per every 100,000 per year (roughly 13,000 new cases diagnosed a year). Fewer than 5% of patients survive five years. Tumor cell differences create challenges for treatment and recovery. The computational pipeline within this project studies the differences between the tumor environment and the surrounding healthy tissue environment where we can eventually identify treatments that reduce the numbers of deaths due to glioblastoma tumors. This tool cuts the time it takes to characterize the tumors by over 90%, making this kind of large-scale research possible for the first time.

Translational Science Solution

A reusable tool that studies brain tumor samples from multiple patients. For each patient, it looks at 3 regions of the brain and analyzes over 2.7 million cells and 6,000 genes. It shows what types of cells are in each region and how they behave. With few changes, this pipeline can also be used to analyze other types of spatial single-cell sequencing data beyond glioblastoma.

Benefits

  • Demonstrated benefits are those that have been observed and are verifiable.
  • Potential benefits are those logically expected with moderate to high confidence.

Gives researchers a reliable and reusable way to study and compare brain tumor tissue samples from many patients at the same time. Demonstrated.

Clinical Benefits:

The pipeline may help researchers learn which parts of a brain tumor are most likely to fight off treatment. This will lead to better and more targeted ways to treat glioblastoma patients.
Potential.

Clinical Benefits:

Created a tool that shows which genes are active inside brain tumors, helping support future research into how to diagnose and treat glioblastoma.
Demonstrated.

Clinical Benefits:

By showing which types of cell and genes are active in each part of the tumor, this pipeline could help researchers find new drug targets for glioblastoma.
Potential.

Clinical Benefits:

Couples two previously stand-alone technologies in a new way to identify transcriptional pathways leading to improved molecular characterization of glioblastomas.
Demonstrated.

Clinical Benefits:

Advances in understanding of glioblastoma tumor biology, supporting research that could lead to better treatments.
Potential.

Community Benefits:

Learning more about how brain tumors work may one day help patients live longer.
Potential.

Community Benefits:

Reduces tumor analysis time by over 90%, lowering the computational resources and time needed for large-scale brain cancer research.
Potential.

Economic Benefits:

Cuts processing from days to hours, reducing research costs for labs studying glioblastoma.
Potential.

Economic Benefits:

Pipeline findings used in research papers to help guide future studies in glioblastoma.
Demonstrated.

Policy Benefits:

This research has clinical, community, economic, and policy implications. The framework for these implications was derived from the Translational Science Benefits Model created by the Institute of Clinical & Translational Sciences at Washington University in St. Louis.

Funding

The National Center for Advancing Translational Sciences (NCATS), NIH under the grant number: 5TL1TR002318

References

  1. Al-Dalahmah, O., et al. (2023). Re-convolving the compositional landscape of primary and recurrent glioblastoma reveals prognostic and targetable tissue states. Nature Communications, 14(1), 2586. https://doi.org/10.1038/s41467-023-38186-1
  2. Liu, Y., et al. (2023). Integration analysis of single-cell and spatial transcriptomics reveal the cellular heterogeneity landscape in glioblastoma and establish a polygenic risk model. Frontiers in Oncology, 13, 1109037. https://doi.org/10.3389/fonc.2023.1109037
  3. Zhao, R., et al. (2025). Blocking ITGA5 potentiates the efficacy of anti-PD-1 therapy on glioblastoma by remodeling tumor-associated macrophages. Cancer Communications, 45(6), 677–701. https://doi.org/10.1002/cac2.70016

Research Team

  • Wenyu Zeng, M.S., Department of Biomedical Informatics and Medical Education, University of Washington
  • Emily E Schneidereit, Ph.D., Department of Lab Medicine and Pathology, University of Washington
  • Cindy Reichel, Ph.D., Department of Lab Medicine and Pathology, University of Washington
  • Jimmy Phuong, MSPH, Ph.D., Department of Biomedical Informatics and Medical Education, University of Washington
  • C.Dirk Keene, M.D., Ph.D., Department of Pathology, University of California San Diego
  • Kristyn Galbraith, M.D., Department of Lab Medicine and Pathology, University of Washington